Home / Posts tagged 'HairDX'

• Genes May Predict Treatment Efficacy For Women Suffering With Hair Loss

  In Uncategorized / By The Bald Truth / 2 March 2010

  A six month pilot study conducted by molecular dermatology and research innovator Hair DX, suggests that certain genetic mechanisms can help predict if the breakthrough hair loss drug Propecia (Finasteride), primary prescribed to men, could actually be effective in the treatment of female pattern hair loss in post menopausal women.

  “Results of our pilot study are very encouraging, as it appears we have found a key piece of the genetic puzzle which identifies women who can benefit from Finasteride therapy in the same way men do. Our findings suggest these women actually have a female corollary to male pattern hair loss (Androgenetic Alopecia), and that is an important finding,” says IAHRS Accepted Member Dr. Sharon Keene, Chief Medical Officer of HairDX. “Once these results are confirmed, it can usher in a new era of treatment for female Androgenetic Alopecia.”

  Read Full Story:

  http://www.news-medical.net/news/20100224/Study-indicates-Finasteride-therapy-may-benefit-women-suffering-from-hair-loss.aspx

   

• HairDX Hair Loss Test Now Sold In Japan

  In Articles, Hair Loss, News / By The Bald Truth / 2 March 2009

  It’s been just about a year since we first reported on HairDX, the breakthrough DNA test that looks for a genetic variant found in most bald men. HairDX has certainly helped American hair loss sufferers make better, more informed choices when considering treating their hair loss. As of this month, Japanese men and women will be able to test for their genetic predisposition for hair loss as well.

  PharmaGenoma, Inc., is the first company ever to introduce a test of this kind. The company announced its exclusive agreement with Aderans Company Limited of Tokyo. This breakthrough test will be available March 1, 2009 in Japan and sold as a HairDX test collection kit. The kit is listed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a Class 1 medical device.

  The simple and accurate genetic test provides clear information that is easy to understand. HairDX analyzes the likelihood of a man or woman developing Androgenetic Alopecia, the most common type of hair loss.

   “Aderans partnership with HairDX will allow people in Japan to learn their risk for hair loss early, so they can choose the best treatment to preserve their hair,” says Katsuji Tokumaru, President of Aderans Co. Ltd. Read more ›